NSW cannabis trial MOU
October 28, 2015
In WHAT NSW Minister for
Medical Research Pru Goward
called an historic achievement
for the state, she and Premier
Mike Baird announced that a
Memorandum of Understanding
(MOU) has been signed with GW
Pharmaceuticals to progress a
major new cannabis research
program (PD 27 Jun).
The research will focus on
children with severe, drug resistant
childhood epilepsy.
Baird said the work was driven by
compassion for those suffering in
the hope that these initiatives will
bring relief to many children and
their loved ones.
“This confirms NSW’s position
as a world leader on medicinal
cannabis and demonstrates the
determination of our Government
to ensure we secure these
groundbreaking trials,” he said.
“Our most vulnerable children will
have access to these innovative and
advanced drugs,” Goward said.
The program forms part of
the NSW Government’s $21m
commitment to medicinal
cannabis reforms, said Goward,
highlighting that the MOU with
GW Pharmaceuticals will facilitate
a world-first Phase 2 clinical trial, a
compassionate access scheme for
Epidiolex (GW’s cannabinoid) and
Phase 3 and 4 trials of the product.
Epidiolex is a non-psychoactive
cannabinoid currently in Phase
3 trials internationally but so far
difficult for Australian children to
access, making the compassionate
scheme a significant breakthrough.
Enquiries can be made by ringing
NSW Health on 1800 217 257.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Oct 15To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Oct 15
